Dr. McCarthy joined CytomX in 2010 as the chief business officer, served as the chief executive officer (CEO) since 2011, and has been the CEO and chairman since 2019. Previously, Dr. McCarthy was a transactional partner at Pappas Ventures. Prior to Pappas, Sean headed business development and strategy at SGX Pharmaceuticals, a structure-based drug discovery company focused on oncology. Earlier in his career he served in various research and development roles at Millennium Pharmaceuticals. Dr. McCarthy is an author on multiple peer-reviewed scientific publications and issued patents. He is a member of the board of directors of Oncoresponse, Inc. and a member of the board of directors and executive committee of California Life Sciences. Dr. McCarthy received his B.S. degree in biochemistry and pharmacology at King’s College, University of London. He also received an M.B.A. from the Rady School of Management at UCSD and a DPhil in cancer biology from St. John’s College, University of Oxford.
Learn MoreDr. Belvin joined CytomX in 2018. Prior to this, Dr. Belvin held roles of increasing responsibility at Genentech where, for over 13 years, she led multiple preclinical pipeline teams and oversaw programs in cancer signaling, cancer metabolism, and cancer immunology. Dr. Belvin began her career at Exelixis where she managed teams responsible for preclinical pipeline discovery within the oncology and inflammation portfolios. Dr. Belvin received her B.A. degree from Harvard University and her Ph.D. from the University of California, Berkeley. Dr. Belvin also trained at the Dana-Farber Cancer Institute and Cold Spring Harbor Laboratory.
Learn MoreMs. Benson brings more than 25 years of CMC experience in the biotechnology industry. Prior to joining CytomX, she was the Senior Vice President, Head of Quality at Coherus BioSciences and also has held various leadership positions at Sutro Biopharma, Jazz Pharmaceuticals, VaxGen and Nabi Biopharmaceuticals (acquired by Biotest Pharmaceuticals). Ms. Benson graduated from the University of North Carolina at Wilmington with a Bachelor of Chemistry and Biology.
Learn MoreWayne brings to CytomX more than 20 years of experience in oncology, in roles ranging from research to medicine to global clinical development. He was previously Chief Medical Officer at Fate Therapeutics, where he oversaw the company’s clinical development strategies of novel immune cell therapies for the treatment of hematologic and solid tumor malignancies. Prior to joining Fate, Wayne spent a decade at Genentech, where he assumed positions of increasing responsibility in Product Development Oncology in the development of the HER2-directed antibody drug conjugate trastuzumab emtansine (Kadcyla). He then joined the Early Clinical Development group in Genentech Research and Early Development in 2011 where he led the early clinical development of molecules covering multiple therapeutic platforms including antibody drug conjugates, checkpoint inhibitors, and immune cell bispecific antibodies, notably the development of polatuzumab vedotin (anti-CD79b antibody drug conjugate), tiragolumab (anti-TIGIT monoclonal antibody) and mosunetuzumab (CD20/CD3 bispecific antibody), and continued to lead the global development of mosunetuzumab in his role in Product Development Oncology at Roche/Genentech. Prior to his clinical development experience, Wayne conducted his clinical training in pediatric hematology-oncology at Johns Hopkins School of Medicine and the National Cancer Institute. He graduated cum laude with a B.A. in Molecular Biology from Princeton University and earned his M.D. with Distinction in Research from the University of Rochester School of Medicine and Dentistry.
Learn MoreMr. Ogden joined CytomX in August of 2021 after a 16-year tenure at Eli Lilly and Company where he held senior financial leadership positions including most recently as chief financial officer of Lilly Diabetes. Prior to his role in Lilly Diabetes, Mr. Ogden was the chief financial officer and treasurer of Lilly del Caribe in Puerto Rico. Over the course of his career at Eli Lilly, Mr. Ogden held financial leadership roles that included drug development, manufacturing, commercial operations, and investor relations. Mr. Ogden received his M.B.A. from Harvard Business School and his B.A. in economics from Wabash College.
Learn MoreDanielle Olander-Moghadassian joined CytomX in 2014, and serves as senior vice president of talent and systems development. She is accountable for optimizing talent, bringing organizational systems to life, and helping the organization to achieve our mission, vision, and values. As an industry innovator, she has developed a strategic plan that includes the creation of a system for aligning corporate goals with business strategy that has resulted in significant growth, scalability, and sustainability at CytomX. Prior to CytomX, Danielle held leadership positions at Portola Pharmaceuticals, SuperGen (now Astex Pharmaceuticals), SUGEN (acquired by Pfizer), and Kinetic Search. She received her B.S. in human resource management from Colorado Technical University.
Learn MoreLeslie Robbins joined CytomX in February 2019 as senior vice president of intellectual property. Ms. Robbins brings more than 25 years of legal experience in the biotechnology industry to CytomX. Most recently, Ms. Robbins was vice president of intellectual property at Coherus BioSciences, a biosimilars company. Prior to that, she held intellectual property roles at Onyx Pharmaceuticals (acquired by Amgen) and Elan Pharmaceuticals. Ms. Robbins began her legal career at a boutique patent firm. Prior to law school, Ms. Robbins was a research associate at Chiron Corporation.
Ms. Robbins received a J.D. from the Chicago-Kent College of Law at the Illinois Institute of Technology and a bachelor’s degree in microbiology and immunology from the University of California, Berkeley.
Learn MoreLloyd Rowland, Jr. joined CytomX in May 2018 as senior vice president, general counsel, secretary, and chief compliance officer. Mr. Rowland brings 25 years of biotechnology and pharmaceutical industry legal counsel and transactional experience to CytomX. Most recently, Mr. Rowland held the position of senior vice president, general counsel and chief compliance officer of Xencor, a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Prior to this, Mr. Rowland held various roles at Amylin Pharmaceuticals throughout his twelve-year career, most recently as vice president and chief compliance officer and previously, as vice president, general counsel and secretary. During his time as general counsel at Amylin, he directed all corporate legal and compliance affairs for the company including the launch of two pharmaceutical products. Prior to joining Amylin, Mr. Rowland served as vice president, secretary and general counsel for Alliance Pharmaceutical Corp. Mr. Rowland received his B.S. degree in economics and political science from Southern Methodist University, and his J.D. from Emory University School of Law.
Learn MoreDr. Robertson joined CytomX in 2020 and currently serves as Senior Vice President, Alliances & Program Leadership. Prior to CytomX, she worked at Johnson & Johnson Innovation, where she was responsible for building and managing a portfolio of strategic partnership opportunities across J&J’s pharma, consumer and medical device sectors. Prior to J&J, she spent several years at the University of California, San Francisco, where she led strategic alliance development and management and served as Program Director for the Grand Multiple Myeloma Translational Initiative and the Sandler Center for Drug Discovery. Dr. Robertson started her career with over a decade at Exelixis in roles of increasing responsibility across research, alliance management and early clinical program leadership and program management. Dr. Robertson holds a B.S. in Chemistry with Honors from the University of Michigan and a PhD in Chemistry from the University of California, Berkeley.
Learn More